Search

Your search keyword '"Teply, Benjamin A."' showing total 28 results
Start Over Author "Teply, Benjamin A." Publication Year Range Last 3 years
28 results on '"Teply, Benjamin A."'

1. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

Author

Stein, Mark N., Dumbrava, Ecaterina E., Teply, Benjamin A., Gergis, Usama S., Guiterrez, Martin E., Reshef, Ran, Subudhi, Sumit K., Jacquemont, Céline F., Senesac, Joseph H., Bayle, J. Henri, Scripture, Charity D., Chatwal, Monica S., Bilen, Mehmet A., Stadler, Walter M., and Becerra, Carlos R.

Published
2024
Full Text
View/download PDF

4. Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression

Author

Alsamraae, Massar, Costanzo-Garvey, Diane, Teply, Benjamin A., Boyle, Shawna, Sommerville, Gary, Herbert, Zachary T., Morrissey, Colm, Dafferner, Alicia J., Abdalla, Maher Y., Fallet, Rachel W., Kielian, Tammy, Jensen-Smith, Heather, deOliveira, Edson I., Chen, Keqiang, Bettencourt, Ian A., Wang, Ji Ming, McVicar, Daniel W., Keeley, Tyler, Yu, Fang, and Cook, Leah M.

Published
2023
Full Text
View/download PDF

6. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.

Author

Marshall, Catherine H., Teply, Benjamin A., Lu, Jiayun, Oliveira, Lia, Wang, Hao, Mao, Shifeng S., Kelly, W. Kevin, Paller, Channing J., Markowski, Mark C., Denmeade, Samuel R., King, Serina, Sullivan, Rana, Davicioni, Elai, Proudfoot, James A., Eisenberger, Mario A., Carducci, Michael A., Lotan, Tamara L., and Antonarakis, Emmanuel S.

Published
2024
Full Text
View/download PDF

7. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer – Clinical Activity and Whole Transcriptome Analysis

Author

Johnson III, Burles A., primary, Teply, Benjamin A., additional, Kagemann, Catherine, additional, McGuire, Bridget, additional, Lombardo, Kara, additional, Jing, Yuezhou, additional, Langbo, William, additional, Epstein, Jonathan I., additional, Netto, George J., additional, Baras, Alex S., additional, Matoso, Andres, additional, McConkey, David J., additional, Gupta, Amol, additional, Ahuja, Nita, additional, Ross, Ashley E., additional, Pierorazio, Phillip M., additional, Comperat, Eva, additional, Hoffman-Censits, Jean, additional, Singla, Nirmish, additional, Patel, Sunil H., additional, Kates, Max, additional, Choi, Woonyoung, additional, Bivalacqua, Trinity J., additional, and Hahn, Noah M., additional

Published
2024
Full Text
View/download PDF

8. Prostate Cancer, Version 3.2024

Author

Schaeffer, Edward M., primary, Srinivas, Sandy, additional, Adra, Nabil, additional, An, Yi, additional, Bitting, Rhonda, additional, Chapin, Brian, additional, Cheng, Heather H., additional, D’Amico, Anthony Victor, additional, Desai, Neil, additional, Dorff, Tanya, additional, Eastham, James A., additional, Farrington, Thomas A., additional, Gao, Xin, additional, Gupta, Shilpa, additional, Guzzo, Thomas, additional, Ippolito, Joseph E., additional, Karnes, R. Jeffrey, additional, Kuettel, Michael R., additional, Lang, Joshua M., additional, Lotan, Tamara, additional, McKay, Rana R., additional, Morgan, Todd, additional, Pow-Sang, Julio M., additional, Reiter, Robert, additional, Roach, Mack, additional, Robin, Tyler, additional, Rosenfeld, Stan, additional, Shabsigh, Ahmad, additional, Spratt, Daniel, additional, Szmulewitz, Russell, additional, Teply, Benjamin A., additional, Tward, Jonathan, additional, Valicenti, Richard, additional, Wong, Jessica Karen, additional, Snedeker, Jenna, additional, and Freedman-Cass, Deborah A., additional

Published
2024
Full Text
View/download PDF

11. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology

Author

Schaeffer, Edward M., primary, Srinivas, Sandy, additional, Adra, Nabil, additional, An, Yi, additional, Barocas, Daniel, additional, Bitting, Rhonda, additional, Bryce, Alan, additional, Chapin, Brian, additional, Cheng, Heather H., additional, D’Amico, Anthony Victor, additional, Desai, Neil, additional, Dorff, Tanya, additional, Eastham, James A., additional, Farrington, Thomas A., additional, Gao, Xin, additional, Gupta, Shilpa, additional, Guzzo, Thomas, additional, Ippolito, Joseph E., additional, Kuettel, Michael R., additional, Lang, Joshua M., additional, Lotan, Tamara, additional, McKay, Rana R., additional, Morgan, Todd, additional, Netto, George, additional, Pow-Sang, Julio M., additional, Reiter, Robert, additional, Roach, Mack, additional, Robin, Tyler, additional, Rosenfeld, Stan, additional, Shabsigh, Ahmad, additional, Spratt, Daniel, additional, Teply, Benjamin A., additional, Tward, Jonathan, additional, Valicenti, Richard, additional, Wong, Jessica Karen, additional, Shead, Dorothy A., additional, Snedeker, Jenna, additional, and Freedman-Cass, Deborah A., additional

Published
2023
Full Text
View/download PDF

13. Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Author

Marshall, Catherine Handy, primary, Teply, Benjamin A., additional, Lim, Su Jin, additional, Wang, Hao, additional, Mao, Shifeng S., additional, Kelly, William Kevin, additional, Paller, Channing Judith, additional, Markowski, Mark Christopher, additional, Denmeade, Samuel R., additional, Carducci, Michael Anthony, additional, Eisenberger, Mario A., additional, King, Serina, additional, Sullivan, Rana, additional, Lotan, Tamara L., additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

16. Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma.

Author

Parikh, Mamta, Pal, Sumanta Kumar, Frankel, Paul Henry, Ruel, Christopher, Mortazavi, Amir, Milowsky, Matthew I., Vaishampayan, Ulka N., Lyou, Yung, Wang, Peng, Parikh, Rahul Atul, Teply, Benjamin A., Dreicer, Robert, Emamekhoo, Hamid, Michaelson, Dror Dror, Hoimes, Christopher J., Zhang, Tian, Srinivas, Sandy, Kim, William Y., Liu, Glenn, and Lara, Primo N

Published
2024
Full Text
View/download PDF

19. Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

Stein, Mark N., primary, Teply, Benjamin A., additional, Gergis, Usama, additional, Strickland, Donald, additional, Senesac, Joseph, additional, Bayle, Henri, additional, Chatwal, Monica Sheila, additional, Bilen, Mehmet Asim, additional, Stadler, Walter Michael, additional, and Dumbrava, Ecaterina Elena, additional

Published
2023
Full Text
View/download PDF

20. Androgen-mediated TGFβ expression suppresses anti-tumor neutrophil response in bone metastatic prostate cancer

Author

Alsamraae, Massar, primary, Costanzo-Garvey, Diane, additional, Teply, Benjamin A., additional, Boyle, Shawna, additional, Sommerville, Gary, additional, Herbert, Zach, additional, Morrissey, Colm, additional, Dafferner, Alicia J., additional, Abdalla, Maher Y., additional, Fallet, Rachel W., additional, Kielian, Tammy, additional, Jensen-Smith, Heather, additional, deOliveira, Edson I., additional, Chen, Keqiang, additional, Bettencourt, Ian A., additional, Wang, Ji Ming, additional, McVicar, Daniel W., additional, Keeley, Tyler, additional, Yu, Fang, additional, and Cook, Leah M., additional

Published
2022
Full Text
View/download PDF

27. NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.

Author

Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, and Freedman-Cass DA

Subjects
Male, Humans, Risk Assessment, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy, Neoplasms, Second Primary
Abstract

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.

Published
2024
Full Text
View/download PDF

28. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.

Author

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, and Freedman-Cass DA

Subjects
Male, Humans, Risk Assessment, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy
Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results